Cibus Global LLC (CBUS) - Net Assets
Based on the latest financial reports, Cibus Global LLC (CBUS) has net assets worth $35.48 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($324.20 Million) and total liabilities ($288.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Cibus Global LLC tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $35.48 Million |
| % of Total Assets | 10.94% |
| Annual Growth Rate | -1.05% |
| 5-Year Change | 54.47% |
| 10-Year Change | 66.39% |
| Growth Volatility | 1377.52 |
Cibus Global LLC - Net Assets Trend (2015–2025)
This chart illustrates how Cibus Global LLC's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Cibus Global LLC to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Cibus Global LLC (2015–2025)
The table below shows the annual net assets of Cibus Global LLC from 2015 to 2025. For live valuation and market cap data, see CBUS market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $21.83 Million | -77.69% |
| 2024-12-31 | $97.83 Million | -71.08% |
| 2023-12-31 | $338.29 Million | +4577.09% |
| 2022-12-31 | $7.23 Million | -48.82% |
| 2021-12-31 | $14.13 Million | -61.68% |
| 2020-12-31 | $36.88 Million | -41.01% |
| 2019-12-31 | $62.51 Million | -33.07% |
| 2018-12-31 | $93.40 Million | +62.50% |
| 2017-12-31 | $57.48 Million | +338.11% |
| 2016-12-31 | $13.12 Million | -45.92% |
| 2015-12-31 | $24.26 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cibus Global LLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 84176900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $79.00K | 0.36% |
| Other Comprehensive Income | $39.00K | 0.18% |
| Other Components | $879.96 Million | 4031.16% |
| Total Equity | $21.83 Million | 100.00% |
Cibus Global LLC Competitors by Market Cap
The table below lists competitors of Cibus Global LLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
GEA Grenobl. Elect.
PA:GEA
|
$97.20 Million |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLACF
|
$97.20 Million |
|
OptiNose
NASDAQ:OPTN
|
$97.22 Million |
|
Amorepacific Group
KO:002795
|
$97.24 Million |
|
Flexopack Société Anonyme Commercial and Industrial Plastics Company
AT:FLEXO
|
$97.15 Million |
|
Polar Capital Technology Trust
LSE:PCT
|
$97.13 Million |
|
Global Lights Acquisition Corp Ordinary Shares
NASDAQ:GLAC
|
$97.11 Million |
|
Favelle Favco Bhd
KLSE:7229
|
$97.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cibus Global LLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 97,831,000 to 21,829,000, a change of -76,002,000 (-77.7%).
- Net loss of 127,085,000 reduced equity.
- New share issuances of 50,100,000 increased equity.
- Other comprehensive income increased equity by 24,000.
- Other factors increased equity by 959,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-127.08 Million | -582.18% |
| Share Issuances | $50.10 Million | +229.51% |
| Other Comprehensive Income | $24.00K | +0.11% |
| Other Changes | $959.00K | +4.39% |
| Total Change | $- | -77.69% |
Book Value vs Market Value Analysis
This analysis compares Cibus Global LLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.46x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.57x to 27.46x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2015-12-31 | $2.28 | $1.31 | x |
| 2016-12-31 | $1.23 | $1.31 | x |
| 2017-12-31 | $6.21 | $1.31 | x |
| 2018-12-31 | $7.61 | $1.31 | x |
| 2019-12-31 | $4.76 | $1.31 | x |
| 2020-12-31 | $2.72 | $1.31 | x |
| 2021-12-31 | $1.22 | $1.31 | x |
| 2022-12-31 | $0.63 | $1.31 | x |
| 2023-12-31 | $32.80 | $1.31 | x |
| 2024-12-31 | $4.21 | $1.31 | x |
| 2025-12-31 | $0.05 | $1.31 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cibus Global LLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -582.18%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3492.31%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 13.97x
- Recent ROE (-582.18%) is below the historical average (-157.71%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -24.28% | -462.97% | 0.05x | 1.07x | $-8.31 Million |
| 2016 | -92.13% | -3029.07% | 0.02x | 1.27x | $-13.40 Million |
| 2017 | -45.20% | -5114.17% | 0.01x | 1.26x | $-31.73 Million |
| 2018 | -29.87% | -11820.76% | 0.00x | 1.27x | $-37.24 Million |
| 2019 | -63.37% | -542.93% | 0.08x | 1.41x | $-45.86 Million |
| 2020 | -121.59% | -187.98% | 0.38x | 1.72x | $-48.52 Million |
| 2021 | -206.62% | -112.36% | 0.70x | 2.63x | $-30.61 Million |
| 2022 | -233.53% | -10758.60% | 0.01x | 3.10x | $-17.61 Million |
| 2023 | -79.11% | -14729.06% | 0.00x | 1.61x | $-301.46 Million |
| 2024 | -256.96% | -5898.36% | 0.01x | 3.58x | $-261.17 Million |
| 2025 | -582.18% | -3492.31% | 0.01x | 13.97x | $-129.27 Million |
Industry Comparison
This section compares Cibus Global LLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $296,451,843
- Average return on equity (ROE) among peers: -36.17%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cibus Global LLC (CBUS) | $35.48 Million | -24.28% | 8.14x | $97.17 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $81.00 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $1.55 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $97.37 Million | -71.81% | 0.35x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $2.46 Million | -172.46% | 1.68x | $33.54 Million |
| Abivax SA American Depositary Shares (ABVX) | $455.01 Million | -73.87% | 0.28x | $7.77 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $3.59 Billion |
About Cibus Global LLC
Cibus, Inc. is an agricultural biotechnology company that develops and licenses gene-edited plant traits. The company's products enable farmers to achieve higher yields and reduce the use of chemicals, such as fungicides, insecticides and fertilizers, and offer sustainable ingredients. it has patented core technology platform, RTDS, a scalable, standardized, end-to-end, semi-automated and high-th… Read more